Developing new treatments for drug-resistant lung infections
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
This study is testing new ways to deliver antibiotics directly to the lungs to help people with serious lung infections caused by tough bacteria like Klebsiella pneumoniae, aiming to make treatments more effective and easier on the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-10641847 on NIH RePORTER |
What this research studies
This research focuses on creating innovative therapies to combat Gram-negative superbugs, particularly Klebsiella pneumoniae, which pose a significant threat to human health. The approach involves direct delivery of antibiotic combinations to the lungs using advanced techniques that enhance drug effectiveness while minimizing side effects. By utilizing novel liposomal therapies and optimizing delivery methods, the research aims to improve treatment outcomes for patients suffering from severe lung infections. The study also incorporates sophisticated modeling to understand how these therapies work in the body.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from severe lung infections caused by Gram-negative bacteria, particularly those who have not responded to standard antibiotic treatments.
Not a fit: Patients with infections caused by non-Gram-negative bacteria or those who are not experiencing severe lung infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with severe lung infections caused by drug-resistant bacteria.
How similar studies have performed: Previous research has shown promise in using innovative delivery methods for antibiotics, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Zhou, Qi — Purdue University
- Study coordinator: Zhou, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.